StockData
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. (DSGN) stock

DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$9.84−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $615.80MP/E –Yield –

Earnings

Design Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 8, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.32
-$0.30 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Design Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 8, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close––-$0.32Release
Q2 FY2026ended Jun 30, 2026Aug 3, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026Apr 28, 2026during market hours––-$0.29Release
Q4 FY2025ended Dec 31, 2025Mar 9, 2026during market hours––-$0.27Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025during market hours––-$0.30Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours–––Release
Q1 FY2025ended Mar 31, 2025May 7, 2025during market hours––-$0.31Release
Q4 FY2024ended Dec 31, 2024Mar 10, 2025before the open––-$0.24Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024during market hours–––Release
Q2 FY2024ended Jun 30, 2024Aug 5, 2024before the open––-$0.21Release
Q1 FY2024ended Mar 31, 2024May 8, 2024during market hours––-$0.20Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Design Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Design Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Design Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Update
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?